About Us

Developing novel, disease-modifying digital therapeutics to improve the lives of patients with neurodegenerative disorders

We are a clinical-stage company dedicated to the development of disease-modifying digital therapeutics to treat neurodegenerative disorders, beginning with Alzheimer’s disease.

Our multi-disciplinary team is comprised of experienced researchers, scientists and software engineers with proven track records in developing digital therapeutics and bringing them to patients. At Cognito, we are developing a new generation of digital therapeutics, with disease-modifying and drug-like effects for patients with neurodegenerative diseases.


Le-Huei Tsai

Li-Huei Tsai, PhD


Dr. Tsai is a founder of Cognito Therapeutics and the Picower Professor of Neuroscience and Director of The Picower Institute of Learning and Memory at MIT. Dr. Tsai's research has focused on elucidating pathogenic mechanisms underlying neurological disorders that affect learning and memory.

Ed Boyden

Ed Boyden, PhD


Dr. Boyden is a founder of Cognito Therapeutics and Y. Eva Tan Professor in Neurotechnology and Professor of Biological Engineering and Brain and Cognitive Sciences at the MIT Media Lab and MIT McGovern Institute. Dr. Boyden’s research focuses on developing tools for analyzing and repairing complex biological systems and using these tools to elucidate fundamental principles about the biological function of these systems.


Advisory Board